Oragenics (OGEN) Convertible Debt (2010 - 2012)

Oragenics' (OGEN) quarterly Convertible Debt came in at $773904.0 in Q1 2012, down 82.8% on a QoQ basis from $4.5 million in Q2 2011.

Oragenics (OGEN) Convertible Debt (2010 - 2012) Analysis & Trends

Oragenics (OGEN) has 3 years of Convertible Debt data on file, last reported at $773904.0 in Q1 2012.

Quarterly Convertible Debt changed N/A year-over-year to $773904.0 in Q1 2012, while the trailing twelve-month figure through Mar 2012 was $773904.0 (changed N/A YoY) and the FY2010 annual result came in at $2.0 million, changed N/A from the prior year.
Convertible Debt declined to $773904.0 in Q1 2012, from $4.5 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $4.5 million in Q2 2011 to a low of $773904.0 in Q1 2012.
A 3-year average of $2.4 million and a median of $2.0 million in 2010 frame the typical range for Convertible Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Oragenics	2.38 Mn	2.38 Mn	-

Download Data